AAD 2023 – Takeda outdoes Bristol’s Sotyktu
TAK-279 comes out on top in the battle of the Tyk2 inhibitors, but biologicals still rule.
Takeda Tyks the deal-making box
For $4bn up front, Takeda buys into the Tyk2 mechanism – and Nimbus and its backers get a huge pay day.
Nimbus hopes to best Bristol’s Sotyktu
Nimbus aims to push Tyk2 inhibition to the limit with its more selective project, but others have a similar idea.
After a record year, where next for biopharma flotations?
2021 was a huge year for IPOs, with pure-play developers raising $14bn, but 2022 is likely to tell a different story.